FindTrial
Sign In

DNX-2401

BIOLOGICAL6 trials

Sponsors

DNAtrix, Inc., Clinica Universidad de Navarra, Universidad de Navarra, University of California, San Francisco, M.D. Anderson Cancer Center

Conditions

Brain CancerBrain NeoplasmBrainstem GliomaCentral Nervous System DiseasesDiffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-MutantEmbryonal Tumor of BrainEpendymoma

Phase 1

DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
CompletedNCT00805376
DNAtrix, Inc.Brain Cancer, Central Nervous System Diseases
Start: 2009-02-28End: 2015-02-28Updated: 2018-07-16
Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas
CompletedNCT03178032
Clinica Universidad de Navarra, Universidad de NavarraBrainstem Glioma, Neoadjuvant Therapy
Start: 2017-05-26End: 2021-01-31Updated: 2023-04-06
Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
Not yet recruitingNCT07444606
M.D. Anderson Cancer CenterMelanoma
Start: 2026-08-31End: 2029-01-01Target: 50Updated: 2026-03-03

Phase 2

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
CompletedNCT02798406
DNAtrix, Inc.Brain Cancer, Brain Neoplasm, Glioblastoma +8
Start: 2016-10-06End: 2021-06-30Updated: 2021-07-15
Combination Therapy for the Treatment of Diffuse Midline Gliomas
RecruitingNCT05009992
University of California, San FranciscoDiffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma +3
Start: 2021-10-20End: 2029-06-30Target: 360Updated: 2025-12-17
Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors
Not yet recruitingNCT07424092
Clinica Universidad de Navarra, Universidad de NavarraEmbryonal Tumor of Brain, Ependymoma, High Grade Glioma +4
Start: 2026-04-01End: 2029-04-01Target: 39Updated: 2026-02-20

Related Papers

Abstract 2895: JAK inhibition enhances virotherapy in gliomas by modulating interferon-driven resistance
Cancer Research2026-04-03
EXTH-89. Precision Targeting of PI3K/mTOR in Diffuse Midline Glioma: GCT007 as a Novel Brain-Penetrant PIK3CA Inhibitor
Neuro-Oncology2025-11-01
TMIC-53. Novel therapy for diffuse midline glioma: Targeting oncohistone drivers with P300/CBP inhibition and Delta-24-RGD
Neuro-Oncology2025-11-01
IMMU-39. T cell receptor diversity is a predictor of therapy response in patients with gliomas treated with Delta-24-RGD
Neuro-Oncology2025-11-01
IMMU-48. Ruxolitinib enhances viroimmunotherapy of gliomas: targeting JAK-guided immunosuppressive pathways
Neuro-Oncology2025-11-01
IMMU-63. Uncovering alternative innate immunity pathways in glioma viroimmunotherapy
Neuro-Oncology2025-11-01
Omnigene-Gut<sup>tm</sup> ensures fecal microbiome stability in the pediatric population.
2024-12-06
EXTH-34. ACETYLATION SUPPRESSION MEETS ONCOLYTIC VIRUSES FOR THE TREATMENT OF PEDIATRIC DIFFUSE MIDLINE GLIOMA
Neuro-Oncology2024-11-01
IMMU-48. CRACKING THE ROLE OF ONCOMETABOLITES IN VIROIMMUNOTHERAPY FOR PEDIATRIC MALIGNANT BRAIN TUMORS
Neuro-Oncology2024-11-01
IMMU-35. TARGETING THE AHR IMMUNOMETABOLIC HUB DURING VIROIMMUNOTHERAPY OF GLIOMAS
Neuro-Oncology2024-11-01
IMMU-11. GUARDIANS OF INNATE IMMUNE ACTIVATION: CRUCIAL ROLES OF NONO AND CGAMP IN GLIOMA VIROTHERAPY
Neuro-Oncology2024-11-01
Rational combination platform trial design for children and young adults with diffuse midline glioma: A report from PNOC
Neuro-Oncology2023-12-202 citations
CTIM-19. ONCOLYTIC DNX-2401 VIROTHERAPY PLUS PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA: A PHASE 1/2 TRIAL
Neuro-Oncology2023-11-015 citations
IMMU-56. TARGETING NONO IN GLIOMA VIROIMMUNOTHERAPY
Neuro-Oncology2023-11-011 citations
EXTH-36. COMBINING ONC201 AND PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA (DMG); THE PRECLINICAL RESULTS UNDERPINNING THE INTERNATIONAL PHASE II CLINICAL TRIAL (NCT05009992)
Neuro-Oncology2023-11-01
EXTH-31. EXPLOITING THE GENETIC DEPENDENCY ON PI3K/MTOR SIGNALING FOR THE TREATMENT OF H3-ALTERED DIFFUSE MIDLINE GLIOMA
Neuro-Oncology2023-11-01
1097 New immunomodulatory roles of NONO pathway during glioma virotherapy
Regular and Young Investigator Award Abstracts2023-10-31
Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.
2023-08-1214 citations
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Nature Medicine2023-05-15225 citations
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Cancer Research2023-05-0574 citations

24 more papers not shown